Hwail Pharm
화일약품 · 061250
Health Care Pharmaceuticals · KOSDAQ
Market cap US$48.7M (₩67.3B)
Overview
Hwail Pharm makes active pharmaceutical ingredients, the chemically active substances that give medicines their effect, as well as finished cephalosporin antibiotics and functional health-food ingredients such as red ginseng and aloe extracts.
Its customers include domestic pharmaceutical companies that source raw drug ingredients or commission finished-antibiotic manufacturing from Hwail. Listed on KOSDAQ, Korea's small-cap board, the company operates across three domestic production sites and runs three distinct business lines: active pharmaceutical ingredients, finished cephalosporin antibiotics, and functional health-food raw materials.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$88.8M
- FY2024US$86.8M
- FY2025US$73.1M
Operating profit
- FY2023US$1.5M
- FY2024US$547.2K
- FY2025−US$1.7M
Net income
- FY2023US$2.8M
- FY2024US$4.7M
- FY2025−US$168.9K
Key ratios (FY2025)
Why it matters
Korean pharmaceutical law requires cephalosporin antibiotics to be made in dedicated, separate facilities, and Hwail holds such a facility, allowing it to contract-manufacture these antibiotics for other domestic drug makers.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?